PHE-885

N/A

Report date: 2025/07/11 20:01:15

Base Information

Drug NamePHE-885
Drug Alias NameAnti-BCMA CAR-T Cell Therapy - Novartis PharmaceuticalsBCMA-directed CAR-T Cell Therapy - Novartis PharmaceuticalsPHE-885
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsImmunologic cytotoxicityT lymphocyte replacements +[4] 
TargetsB-cell maturation protein
Therapy Area/IndicationsHematologic NeoplasmsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[14] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag
Inactive CompaniesN/A
Active IndicationsHematologic Neoplasms
Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksN/A